LLY Stock Eli Lilly and Company
STRONG BUY US · NYSEObesity and diabetes medicine leadership remains a powerful earnings and momentum catalyst.
Future value: $1,331.55 (+4.10%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Strong momentum and raised analyst targets support continued accumulation.
- ▸Above 50-day MA (+7.62%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (91.8% of range) — strength
Is LLY a buy right now?
Trend: LLY is trading above the 50-day average (+7.62%), RSI 41 — neutral momentum, with a 3-month return of +4.79%.
Valuation & quality: Eli Lilly and Company trades on a trailing P/E of 42.9, forward P/E 27.0, PEG 1.23, price-to-book 33.66; fundamentals show net margin 33.5%, return on equity 102.3%, revenue growth 47.7% year on year.
Analyst consensus: 30 analysts have a mean 12-month price target of $1333.72 (+4.3% vs the last close; range $930.00 – $1600.00), consensus rating “buy”.
Income: trailing dividend yield 0.54%.
Our screen: STRONG BUY (score 4) — Obesity and diabetes medicine leadership remains a powerful earnings and momentum catalyst.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -12.60% | +1.60% | +18.20% | +8.50% | -4.20% | +0.70% | +0.00% | +10.50% |
Fundamentals
Analyst price target
Technical signals
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 50,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.